Clinical Trial: A Study in Healthy Subjects to Assess the Safety and Tolerability of a 120-hour Continuous Infusion of M6229

U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07285603) titled 'A Study in Healthy Subjects to Assess the Safety and Tolerability of a 120-hour Continuous Infusion of M6229' on Sept. 29.

Brief Summary: This is a Phase I, single-center, randomized, single-blind, placebo-controlled study in healthy subjects assessing the safety, tolerability and pharmacokinetic profile of three different dose levels of M6229 when administered continuously for 120 hours.

Study Start Date: Nov. 21, 2024

Study Type: INTERVENTIONAL

Condition: Healthy Subjects

Intervention: DRUG: M6229

Continuous 120-hour intravenous infusion of M6229

DRUG: Placebo

Continuous 120-hour intravenous infusion of placebo (saline) ...